(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out How to Track the Establishment of New 5G Pinnacles - 2Carina Nebula shines with white-blue stars | Space photo of the day for Jan. 5, 2026
- 3Will your baby get a hep B vaccine? What RFK panel's ruling means.
- 4Excursion to Different Universes: the Top Sci-fi Motion pictures Ever
- 5IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- Young Muslims in Germany feel left out of Mideast debate, experts say
- Skeleton of famed musketeer possibly found in Dutch church
- Beating Wellbeing Difficulties: Individual Victories in Health
- Cocoa Prices Sink on Favorable Crop Conditions in West Africa
- Hezbollah fires over 600 times at Israel, IDF troops over last 24 hours
- 4K televisions for Extreme Film Watching Experience
- Volcanic eruption led to the Black Death, new research suggests
- What Middle East Conflict Could Mean For The World’s Largest Whale Shark Gathering
- France will build a new aircraft carrier as it increases defense spending
